Orion and Innothéra settle their dispute regarding

Orion Corporation and Laboratoire Innothéra S.A. from France have settled their dispute concerning the distribution of Orion Pharma's Divina hormone replacement therapy (HRT) products in France. Accordingly, Innothéra and Orion, respectively, have withdrawn their claims and counter claims that were pending in an arbitration procedure before the ICC in Paris. In accordance with the mutual understanding reached between the two companies, Innothéra will continue marketing Divina in France, largely on the basis of the original agreement.

Orion Pharma and Innothéra have agreed to reinforce their collaboration in support of Innothéra's efforts to successfully promote Divina on the French market. Orion will contribute to the promotional activities of Innothéra in a way separately agreed upon between the parties.


Orion Corporation


Markku Talonen
President and CEO

Pauli Torkko
Executive Vice President